March 4, 2013 - Atlanta, GA. The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women’s health organizations, today called on US government agencies to coordinate a national agenda that will quickly and accurately answer questions about how the antiretroviral (ARV) drug Truvada can best be made available as an HIV prevention option for women at risk of HIV infection. Continue Reading...
Do you get our newsletter?
Sign up for our monthly Newsletter and get the latest info in you in box.
The 2009 WRI meeting aimed to identify and then prioritize research questions in order to determine the area of focus that would most significantly impact our understanding of HIV disease in women.
Learn about different types of diabetes, its symptoms, glucose tests, treatments, why diabetes can be important to HIV+ people, and more.